IE43381B1 - Antigenic compositions - Google Patents
Antigenic compositionsInfo
- Publication number
- IE43381B1 IE43381B1 IE1248/76A IE124876A IE43381B1 IE 43381 B1 IE43381 B1 IE 43381B1 IE 1248/76 A IE1248/76 A IE 1248/76A IE 124876 A IE124876 A IE 124876A IE 43381 B1 IE43381 B1 IE 43381B1
- Authority
- IE
- Ireland
- Prior art keywords
- erythrocytes
- adhesion factor
- composition
- antigenic
- antigenic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 230000000890 antigenic effect Effects 0.000 title claims description 26
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 38
- 241000287828 Gallus gallus Species 0.000 claims abstract description 15
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 7
- 230000032696 parturition Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 15
- 230000035931 haemagglutination Effects 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000003022 colostrum Anatomy 0.000 claims description 5
- 235000021277 colostrum Nutrition 0.000 claims description 5
- 230000000369 enteropathogenic effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 2
- 230000010065 bacterial adhesion Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 14
- 239000000427 antigen Substances 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 241000282887 Suidae Species 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000181 anti-adherent effect Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010033478 E coli K88 antigen Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 231100000249 enterotoxic Toxicity 0.000 description 2
- 230000002242 enterotoxic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 241000220438 Arachis Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000449980 Mansa Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020243 first infant milk formula Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB25221/75A GB1553664A (en) | 1975-06-12 | 1975-06-12 | Antigenic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE43381L IE43381L (en) | 1976-12-12 |
| IE43381B1 true IE43381B1 (en) | 1981-02-11 |
Family
ID=10224176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1248/76A IE43381B1 (en) | 1975-06-12 | 1976-06-10 | Antigenic compositions |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS51151322A (enExample) |
| AU (1) | AU513801B2 (enExample) |
| BE (1) | BE842814A (enExample) |
| CA (1) | CA1061252A (enExample) |
| DE (1) | DE2626350C2 (enExample) |
| DK (1) | DK146312C (enExample) |
| ES (1) | ES448827A1 (enExample) |
| FR (1) | FR2313942A1 (enExample) |
| GB (1) | GB1553664A (enExample) |
| IE (1) | IE43381B1 (enExample) |
| IT (1) | IT1078623B (enExample) |
| NL (1) | NL7606379A (enExample) |
| ZA (1) | ZA763370B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ205392A (en) * | 1982-09-02 | 1987-03-06 | Unilever Plc | Preparation of immunoglobulins against e.coli pili |
| DK219084D0 (da) * | 1984-05-02 | 1984-05-02 | Frederik Carl Peter Lindberg | Antigen |
| IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
-
1975
- 1975-06-12 GB GB25221/75A patent/GB1553664A/en not_active Expired
-
1976
- 1976-06-07 ZA ZA00763370A patent/ZA763370B/xx unknown
- 1976-06-07 AU AU14705/76A patent/AU513801B2/en not_active Expired
- 1976-06-10 FR FR7617555A patent/FR2313942A1/fr active Granted
- 1976-06-10 CA CA254,599A patent/CA1061252A/en not_active Expired
- 1976-06-10 IE IE1248/76A patent/IE43381B1/en unknown
- 1976-06-10 BE BE167812A patent/BE842814A/xx not_active IP Right Cessation
- 1976-06-11 DK DK263076A patent/DK146312C/da not_active IP Right Cessation
- 1976-06-11 JP JP51068603A patent/JPS51151322A/ja active Pending
- 1976-06-11 DE DE2626350A patent/DE2626350C2/de not_active Expired
- 1976-06-11 ES ES448827A patent/ES448827A1/es not_active Expired
- 1976-06-14 NL NL7606379A patent/NL7606379A/xx not_active Application Discontinuation
- 1976-06-14 IT IT68467/76A patent/IT1078623B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| AU513801B2 (en) | 1981-01-08 |
| NL7606379A (nl) | 1976-12-14 |
| FR2313942A1 (fr) | 1977-01-07 |
| DK146312B (da) | 1983-09-05 |
| ZA763370B (en) | 1978-01-25 |
| IT1078623B (it) | 1985-05-08 |
| BE842814A (fr) | 1976-12-10 |
| DE2626350C2 (de) | 1984-09-13 |
| CA1061252A (en) | 1979-08-28 |
| FR2313942B1 (enExample) | 1979-01-12 |
| DK146312C (da) | 1984-02-20 |
| JPS51151322A (en) | 1976-12-25 |
| DE2626350A1 (de) | 1977-05-12 |
| DK263076A (da) | 1976-12-13 |
| AU1470576A (en) | 1977-12-15 |
| GB1553664A (en) | 1979-09-26 |
| IE43381L (en) | 1976-12-12 |
| ES448827A1 (es) | 1977-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adam et al. | Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis | |
| CA2517911C (en) | Composition and method for the treatment and prevention of enteric bacterial infections | |
| US5258178A (en) | Method and product for the treatment of gastric disease | |
| US4136167A (en) | Process for reducing the incidence of neonatal diarrhoea in pigs | |
| JP2002501526A (ja) | 乳汁における免疫グロブリンａの生成方法 | |
| JPH0657663B2 (ja) | 多機能特異的抗体の製造方法 | |
| KR100221452B1 (ko) | 장감염에 대한 백신조성물의 제조방법 | |
| JPS58146513A (ja) | 鳥感染性気管支炎ワクチン | |
| CA1184115A (en) | Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines | |
| JPH02160726A (ja) | ワクチン | |
| AU705186B2 (en) | Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection | |
| JP2004137286A (ja) | 腸原生動物のワクチン類 | |
| Panigrahy et al. | Antibiotic-induced immunosuppression and levamisole-induced immunopotentiation in turkeys | |
| Ingram et al. | Immunological responses of young animals. I. Review of the literature | |
| EP3883603A1 (en) | A vaccine for protection against streptococcus suis | |
| IE43381B1 (en) | Antigenic compositions | |
| JP3072353B2 (ja) | 胃炎，胃または十二指腸潰瘍予防食品 | |
| EP0930316B1 (en) | Oral product for the prevention and treatment of infectious gastroenteritides in calves | |
| RU2043771C1 (ru) | Вакцина против эшерихиоза животных | |
| Schmidt et al. | Immunodiffusion reactions with rubella antigens | |
| KR100423983B1 (ko) | 대장균, 살모넬라 엔테라이티디스, 살모넬라 티피뮤리움, 전염성 위장염 바이러스에 대한 특수면역단백질을 공유하는 계란생산방법과 그 생산방법으로 제조된 특수면역단백질을 함유한 계란, 난황, 사료 | |
| Gay et al. | Studies on colibacillosis of calves. I. The antibody acquired by calves as the result of vaccination of the dam | |
| Tarrant et al. | Serological characteristics and general chemical nature of the in vitro exoantigens of T. cruzi | |
| RU2043772C1 (ru) | Способ получения сыворотки, антиадгезивной и антитоксической против эшерихиоза сельскохозяйственных животных | |
| Brotherston et al. | Development of a non-infective protective antigen against louping-ill (arborirus group B): Laboratory experiments |